Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Taps Mosaic to Develop Reimbursement Plan for Ovarian Cancer Dx

NEW YORK (GenomeWeb News) - Mosaic Health Care Consultants has agreed to develop reimbursement strategies and programs for Ciphergen Biosystems' ovarian cancer test, Ciphergen said yesterday. 
 
Ciphergen's ovarian cancer triage test, which the company plans to submit for FDA approval after it completes clinical trials, uses a biomarker panel to measure risk stratification.
 
Ciphergen president and CEO Gail Page said in a statement that developing a reimbursement plan is for the test is "one crucial aspect of gaining rapid adoption by the medical community."
 
Earlier this week, the company said it had hired the consulting company Emergo to help it gain European CE Mark clearance for the test.
 
Ciphergen has an existing agreement with Quest Diagnostics to commercialize the biomarker-based test after FDA approval.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.